Dr. Suzette Sutherland

Unfortunately, there's data that shows that carcinoma in situ, or CIS, was missed on TURBT more than 45% of the time on subsequent radical cystectomy cases. And 86% of residual tumors have been found at the original resection site. With this, it's clear that enhanced visualization is of utmost importance and will be a significant benefit during TURBT.

Unfortunately, there's data that shows that carcinoma in situ, or CIS, was missed on TURBT more than 45% of the time on subsequent radical cystectomy cases. And 86% of residual tumors have been found at the original resection site. With this, it's clear that enhanced visualization is of utmost importance and will be a significant benefit during TURBT.

Unfortunately, there's data that shows that carcinoma in situ, or CIS, was missed on TURBT more than 45% of the time on subsequent radical cystectomy cases. And 86% of residual tumors have been found at the original resection site. With this, it's clear that enhanced visualization is of utmost importance and will be a significant benefit during TURBT.

Furthermore, patient compliance can often be an issue, with only 23% of patients coming back for re-resection. It's therefore all the more important to ensure a complete TURBT The first time, right from the start. Listen to this podcast interview with Dr. Suzanne Merrow, who discusses the benefits of blue light cystoscopy to enhance visualization and ensure a high quality TURBT.

Furthermore, patient compliance can often be an issue, with only 23% of patients coming back for re-resection. It's therefore all the more important to ensure a complete TURBT The first time, right from the start. Listen to this podcast interview with Dr. Suzanne Merrow, who discusses the benefits of blue light cystoscopy to enhance visualization and ensure a high quality TURBT.

Furthermore, patient compliance can often be an issue, with only 23% of patients coming back for re-resection. It's therefore all the more important to ensure a complete TURBT The first time, right from the start. Listen to this podcast interview with Dr. Suzanne Merrow, who discusses the benefits of blue light cystoscopy to enhance visualization and ensure a high quality TURBT.

I'm your host today, Dr. Suzette Sutherland, and I'm super excited to have Dr. Suzanne Merrill here today to talk to us about diagnostic aspects of bladder cancer and how to enhance that, specifically with a newer type of technology called blue light cystoscopy. Thanks for being here with us today, Dr. Merrill. It's my pleasure. Thanks for having me, Suzette.

I'm your host today, Dr. Suzette Sutherland, and I'm super excited to have Dr. Suzanne Merrill here today to talk to us about diagnostic aspects of bladder cancer and how to enhance that, specifically with a newer type of technology called blue light cystoscopy. Thanks for being here with us today, Dr. Merrill. It's my pleasure. Thanks for having me, Suzette.

I'm your host today, Dr. Suzette Sutherland, and I'm super excited to have Dr. Suzanne Merrill here today to talk to us about diagnostic aspects of bladder cancer and how to enhance that, specifically with a newer type of technology called blue light cystoscopy. Thanks for being here with us today, Dr. Merrill. It's my pleasure. Thanks for having me, Suzette.

Yeah, let me tell you a little bit about Dr. Suzanne Merrill. She is trained at Duke University for her urology residency and then did a GU oncology fellowship at Mayo Clinic in 2015. She's now 10 years out of fellowship, so she has a lot of experience under her belt. She started on faculty at Penn State Hershey Medical Center. where she was program director there too for the urology residents.

Yeah, let me tell you a little bit about Dr. Suzanne Merrill. She is trained at Duke University for her urology residency and then did a GU oncology fellowship at Mayo Clinic in 2015. She's now 10 years out of fellowship, so she has a lot of experience under her belt. She started on faculty at Penn State Hershey Medical Center. where she was program director there too for the urology residents.

Yeah, let me tell you a little bit about Dr. Suzanne Merrill. She is trained at Duke University for her urology residency and then did a GU oncology fellowship at Mayo Clinic in 2015. She's now 10 years out of fellowship, so she has a lot of experience under her belt. She started on faculty at Penn State Hershey Medical Center. where she was program director there too for the urology residents.

And now since about a few years, since 2021, she's in Colorado at Colorado Urology, which is under a bigger umbrella of United Urology and specializing in GU oncology and also considered a regional bladder cancer specialist. So she really knows what she's talking about here today. And I'm so happy that she's here to share that with us today. Well, thank you. So let's just get started.

And now since about a few years, since 2021, she's in Colorado at Colorado Urology, which is under a bigger umbrella of United Urology and specializing in GU oncology and also considered a regional bladder cancer specialist. So she really knows what she's talking about here today. And I'm so happy that she's here to share that with us today. Well, thank you. So let's just get started.

And now since about a few years, since 2021, she's in Colorado at Colorado Urology, which is under a bigger umbrella of United Urology and specializing in GU oncology and also considered a regional bladder cancer specialist. So she really knows what she's talking about here today. And I'm so happy that she's here to share that with us today. Well, thank you. So let's just get started.

Like, first of all, just a couple of, you know, good fun facts, I suppose, not so fun. But, you know, we know bladder cancer, it seems like it's getting even more common today than it was even when I was training. It's quite common, more so in men than women. Tell us the statistics around the epidemiology today.

Like, first of all, just a couple of, you know, good fun facts, I suppose, not so fun. But, you know, we know bladder cancer, it seems like it's getting even more common today than it was even when I was training. It's quite common, more so in men than women. Tell us the statistics around the epidemiology today.

Like, first of all, just a couple of, you know, good fun facts, I suppose, not so fun. But, you know, we know bladder cancer, it seems like it's getting even more common today than it was even when I was training. It's quite common, more so in men than women. Tell us the statistics around the epidemiology today.

Right. So we know when we talk to patients about cancer, oftentimes I say the C word before I say the word, right? Because it's so frightening, right? And we as physicians and surgeons know that one person's cancer isn't another person's cancer, especially when we're talking about different organs, right?

Right. So we know when we talk to patients about cancer, oftentimes I say the C word before I say the word, right? Because it's so frightening, right? And we as physicians and surgeons know that one person's cancer isn't another person's cancer, especially when we're talking about different organs, right?